DARK SECRETS: 24 | Vintage Vibes

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an 8-year-old boy who had received Elevidys, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) gene therapy for Duchenne muscular dystrophy.

Benzinga · Jul 28, 2025

Ireland's 'Economic Miracle' At Risk From Tariffs

The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.

International Business Times · Jul 28, 2025

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo CEO ousted in May, in place until successor named

The Independent UK · Jul 28, 2025

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003.

Benzinga · Jul 25, 2025

Centene Clocks First Quarterly Loss In 13 Years, Stock Volatile (UPDATED)

Editor’s Note: The story has been updated with executive comment and stock price change

Benzinga · Jul 25, 2025

West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars

West Pharmaceutical Services, Inc. (NYSE:WST) shares are surging Thursday after the injectable pharmaceutical packaging and delivery systems company delivered a robust beat on its second-quarter 2025 earnings and revenue, while also significantly raising its full-year guidance.

Benzinga · Jul 24, 2025

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Benzinga · Jul 23, 2025

Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come.

Benzinga · Jul 23, 2025

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.

Benzinga · Jul 22, 2025

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators

The Independent UK · Jul 22, 2025